Pre-Treatment HBV Activation Modulates Circulating Immune Markers in Hepatocellular Carcinoma Patients Undergoing TACE Plus ICIs and Anti-VEGF Antibodies/TKIs
Pre-treatment HBV activation is linked to altered baseline immune profiles, particularly elevated IgA, and influences early IgA dynamics. Early IgA changes independently predict early treatment response, supporting the integration of IgA-based immune profiling into personalized strategies for HBV-related uHCC.
Authors
- Lihao Qin
- Hao Yang (ORCID: https://orcid.org/0009-0000-8509-7523)
- Linzhou Zhu
- Jian Shen
- Xiaoli Zhu
- Yu Wang
Institutions
- Soochow University (CN)
- First Affiliated Hospital of Soochow University (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2026-02-01
- DOI
- https://doi.org/10.2147/cmar.s563546
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Natural Science Foundation of Jiangsu Province
- Soochow University